1. The Path to Group A Streptococcus Vaccines: World Health Organization Research and Development Technology Roadmap and Preferred Product Characteristics
- Author
-
David Dc Kaslow, Katherine L. O'Brien, Andrew C Steer, Jerome H. Kim, Fernando Gouvea-Reis, Jean-Louis Excler, Jonathan R. Carapetis, Pierre R. Smeesters, Chris A. Van Beneden, and Johan Vekemans
- Subjects
0301 basic medicine ,Microbiology (medical) ,Biomedical Research ,Streptococcus pyogenes ,media_common.quotation_subject ,Global Health ,World Health Organization ,World health ,03 medical and health sciences ,Strategic goal ,0302 clinical medicine ,Cost of Illness ,Streptococcal Infections ,vaccine ,Global health ,Humans ,Medicine ,030212 general & internal medicine ,Antibiotic use ,Policy Making ,media_common ,business.industry ,group A Streptococcus ,Streptococcal Vaccines ,pharyngitis ,Sciences bio-médicales et agricoles ,rheumatic heart disease ,Product characteristics ,Vaccine efficacy ,3. Good health ,Viewpoints ,030104 developmental biology ,Infectious Diseases ,Risk analysis (engineering) ,Technology roadmap ,business ,Diversity (politics) - Abstract
Group A Streptococcus (GAS) infections result in a considerable underappreciated burden of acute and chronic disease globally. A 2018 World Health Assembly resolution calls for better control and prevention. Providing guidance on global health research needs is an important World Health Organization (WHO) activity, influencing prioritization of investments. Here, the role, status, and directions in GAS vaccines research are discussed. WHO preferred product characteristics and a research and development technology roadmap, briefly presented, offer an actionable framework for vaccine development to regulatory and policy decision making, availability, and use. GAS vaccines should be considered for global prevention of the range of clinical manifestations and associated antibiotic use. Impediments related to antigen diversity, safety concerns, and the difficulty to establish vaccine efficacy against rheumatic heart disease are discussed. Demonstration of vaccine efficacy against pharyngitis and skin infections constitutes a key near-term strategic goal. Investments and collaborative partnerships to diversify and advance vaccine candidates are needed., Group A Streptococcus causes a wide spectrum of acute and chronic human disease and considerable antibiotic use. Through a consensus-building consultation process, the World Health Organization developed a vision for vaccine development, highlighting strategic targets, product preferences, and priority research/development activities.
- Published
- 2019